Kronos Bio, Inc. KRON
0.88 0.00 (+0.00%)
At closeJun 20, 2025, 4:00 PM EDT
0.8701 Day range 0.881
52-week range unavailable
- Market cap
- 57.32M
- Revenue (ttm)
- 8.41M
- Shares out
- 60.34M
- Forward P/E
- -0.69
- Volume
- 53.69K
- Open
- 0.881
- Previous close
- 0.88
- Day's range
- 0.8701 – 0.881
- Beta
- 1.86
- Price target
- 2.25 (+155.7%)
- Earnings date
- Aug 8, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- -58.20M
- PEG ratio
- 0.00
- Price / sales
- 6.81
- Price / book
- 0.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 44.20%
- Free cash flow
- -43.46M
- Total cash
- 136.65M
- Total debt
- 27.13M
- Return on equity
- -63.00%
- Short % of float
- 1.15%
- 50-day average
- 0.9384
- 200-day average
- 1.04
Analyst view
Price target (mean) 2.25
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
KRON Revenue — quarterly 1.86M
KRON Net income — quarterly -8.36M
KRON EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.26 | -0.23 | +0.03 | +11.54% |
| Aug 8, 2024 | Jun 1, 2024 | -0.32 | -0.27 | +0.05 | +15.63% |
| Aug 8, 2024 | Jun 1, 2024 | -0.32 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.43 | -0.50 | -0.07 | -16.28% |
| May 9, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.51 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 19, 2023 | Piper Sandler | main | Overweight | Overweight |
| Dec 19, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 27, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kronosbio.com
News
Kronos Bio Completes Sale to Concentra Biosciences 
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON 
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders 
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders 
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right 
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
Your note
Sign in to keep a note on KRON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AL-WAKEEL YASIR B | Chief Financial Officer | Sale | Jul 5, 2023 | 346,102 |
| BISCHOFBERGER NORBERT W | Chief Executive Officer | Purchase | Jun 27, 2024 | 0 |
| DIMARTINO JORGE M.D. PH.D. | Officer | Sale | Jan 3, 2024 | 315,246 |
| DINSMORE CHRISTOPHER | Officer | Sale | Jan 3, 2024 | 260,969 |
| FRISBEE ALLISON | Officer | Sale | Feb 20, 2024 | 204,510 |
| KNOBELMAN DEBORAH A | Chief Financial Officer | Stock Award(Grant) | Jun 2, 2024 | 164,260 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vida Ventures Advisors, LLC | 4.58% | 2,765,314 | 2.63M | Sep 29, 2024 |
| Millennium Management Llc | 3.39% | 2,045,803 | 1.94M | Sep 29, 2024 |
| Vanguard Group Inc | 3.19% | 1,922,809 | 1.83M | Sep 29, 2024 |
| Partners Capital Investment Group, LLP | 2.67% | 1,611,512 | 1.53M | Sep 29, 2024 |
| Alphabet Inc. | 2.38% | 1,438,232 | 1.37M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 2.16% | 1,304,511 | 1.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19% | 1,318,872 | 1.25M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 559,541 | 531.56K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 244,188 | 231.98K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.20% | 118,927 | 112.98K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.17% | 100,146 | 95.14K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 76,509 | 72.68K | Oct 30, 2024 |